News Agency
Men's Weekly

  • Written by PR Newswire
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

23rd Annual Needham Virtual Healthcare Conference

Presentation Time

Thursday, April 11 at 10:15 a.m. EST

Presenters

Raj Kannan, CEO; John Hayslip CMO

Webcast link

Here

Meetings

One-on-one and small group meetings: April 11, 2024

ManagementParticipants

Raj Kannan, CEO

Joe Skelton, CFO

John Hayslip, CMOTyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab's IR websiteat http://ir.i-mabbiopharma.com/

For more information, please contact your Needham representative.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.

For more information, please contact:Tyler EhlerSenior Director, Investor RelationsIR@imabbio.com 

Read more https://www.prnasia.com/story/archive/4380019_CN80019_0

Air Conditioner Sales Melbourne Helping You Choose The Right Cooling Solution

Creating a comfortable indoor environment often starts with choosing the right system, and that’s where air conditioner sales Melbourne become more than just a purchase decision. It’s about finding a solution that aligns with your space, lifestyle, and energy needs. With... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion